Treat-to-Target or High-Intensity Statin in Patients With Coronary Artery Disease: A Randomized Clinical Trial.

rct

• numeric_findings[0]

  {"unit":null,"label":"reported_value","value_text":"50"}

  View evidence

  • CONCLUSIONS_AND_RELEVANCE · CONCLUSIONS_AND_RELEVANCE:S001

    “”

• numeric_findings[1]

  {"unit":null,"label":"reported_value","value_text":"12"}

  View evidence

  • DESIGN_SETTING_AND_PARTICIPANTS · DESIGN_SETTING_AND_PARTICIPANTS:S001

    “”

• numeric_findings[2]

  {"unit":null,"label":"reported_value","value_text":"50"}

  View evidence

  • IMPORTANCE · IMPORTANCE:S001

    “”

• numeric_findings[3]

  {"unit":null,"label":"reported_value","value_text":"50"}

  View evidence

  • INTERVENTIONS · INTERVENTIONS:S001

    “”

• numeric_findings[4]

  {"unit":null,"label":"reported_value","value_text":"3"}

  View evidence

  • MAIN_OUTCOMES_AND_MEASURES · MAIN_OUTCOMES_AND_MEASURES:S001

    “”

• population

  {"description":"Among patients with coronary artery disease, a treat-to-target LDL-C strategy of 50 to 70 mg/dL as the goal was noninferior to a high-intensity statin therapy for the 3-year composite of death, myocar","sample_size":null,"exclusion_summary":null,"inclusion_summary":null}

  View evidence

  • CONCLUSIONS_AND_RELEVANCE · CONCLUSIONS_AND_RELEVANCE:S001

    “”

• authors_conclusion
• comparator
• extension.rct_extension.allocation_ratio
• extension.rct_extension.blinding
• extension.rct_extension.itt_or_per_protocol
• extension.rct_extension.primary_endpoint
• extension.rct_extension.randomization_method
• extension.rct_extension.sample_size_arms
• intervention
• key_results
• limitations
• primary_outcome
• safety_findings

• PharmaLens analyzed the title, abstract, and available metadata—not the full text.
• This page is not medical advice.
• Scores and ranks shown in search are query-relative relevance only — not evidence quality.
• Similarity neighbors do not imply support or contradiction.
• Cover media kind: deterministic_cover
• Extraction schema: pharmalens.article-intelligence.v1
• Revision: 1

• Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
• Lecanemab in Early Alzheimer's Disease.
• Learning implementation of a guideline based decision support system to improve hypertension treatment in primary care in China: pragmatic cluster randomised controlled trial.
• Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial.
• Evidence Neighborhood preview: Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial.
• Evidence Neighborhood preview: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
• Evidence Neighborhood preview: Lecanemab in Early Alzheimer's Disease.
• Evidence Neighborhood preview: Learning implementation of a guideline based decision support system to improve hypertension treatment in primary care in China: pragmatic cluster randomised controlled trial.

Relatedness is similarity or shared entities — not support or contradiction.